

Amendments to the Claims:

Please cancel claims 15-22 and 74-80. Per 37 C.F.R. §1.121, the current status of all the claims in the present application is presented below. This listing of the claims will replace all prior versions and listing of the claims in the present application:

1. – 54. (Canceled)

55. (Previously presented) An antibody comprising a monoclonal antibody that specifically binds to an antigenic epitope of human IL-22RA (SEQ ID NO:3) amino acid number 1 (Pro), to amino acid number 6 (Asp) of SEQ ID NO:3; wherein the antibody reduces or neutralizes the activity of either human IL-22 (SEQ ID NO:6) or IL-20 (SEQ ID NO:8).

56. (Original) The antibody of claim 55, wherein the antibody reduces or neutralizes the activity of both human IL-22 (SEQ ID NO:6) and IL-20 (SEQ ID NO:8).

57. (Original) The antibody of claim 55, wherein the antibody is selected from the group consisting of: (a) a murine monoclonal antibody, (b) a humanized antibody derived from (a), (c) an antibody fragment, and (d) a human monoclonal antibody.

58. (Original) The antibody of claim 57, wherein the antibody further comprises PEGylation.

59. (Original) The antibody of claim 56, wherein the antibody is selected from the group consisting of: (a) a murine monoclonal antibody, (b) a humanized antibody derived from (a), (c) an antibody fragment, and (d) a human monoclonal antibody.

60. (Original) The antibody of claim 59, wherein the antibody further comprises PEGylation.

61. – 80. (Canceled)